The ORR of 46% for patients receiving dostarlimab plus chemotherapy was also comparable to that for patients with advanced (Stage IV) non-squamous NSCLC receiving the anti-PD-L1 antibody atezolizumab plus chemotherapy (carboplatin plus nanoparticle albumin-bound paclitaxel) as 1 L treatment in the IMpower130 study (49%)16. This evidence concerns the gene CD274 and non-small cell lung carcinoma.